We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-11.26%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$800M
AUM Growth
-$414M
Cap. Flow
-$240M
Cap. Flow %
-29.97%
Top 10 Hldgs %
59.99%
Holding
111
New
25
Increased
21
Reduced
27
Closed
33

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$26.8M
2
MRK icon
Merck
MRK
+$25.8M
3
PFE icon
Pfizer
PFE
+$19.8M
4
ABBV icon
AbbVie
ABBV
+$14.1M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$13.5M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$21.3M
2
VRNT
Verint Systems
VRNT
+$16.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$12.8M
4
VTRS icon
Viatris
VTRS
+$11.3M
5
PTCT icon
PTC Therapeutics
PTCT
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 65.88%
2 Technology 4.53%
3 Consumer Discretionary 1.29%
4 Communication Services 0.33%
5 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIOX
26
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$7.15M 0.89%
2,931,018
+2,532,477
+635% +$9.14M
PASG icon
27
Passage Bio
PASG
$14.4M
$7.13M 0.89%
+23,909
New +$7.48M
ACAD icon
28
Acadia Pharmaceuticals
ACAD
$4.43B
$6.63M 0.83%
157,000
-200,000
-56% -$8.24M
BPMC
29
DELISTED
Blueprint Medicines
BPMC
$6.4M 0.8%
109,500
+3,500
+3% +$225K
ARVN icon
30
Arvinas
ARVN
$518M
$5.88M 0.73%
145,781
-53,000
-27% -$2.48M
ADMA icon
31
ADMA Biologics
ADMA
$1.96B
$5.29M 0.66%
1,838,100
+1,298,100
+240% +$4.49M
CRM icon
32
Salesforce
CRM
$151B
$5.12M 0.64%
+35,529
New +$6.09M
TRIL
33
DELISTED
Trillium Therapeutics Inc.
TRIL
$5.09M 0.64%
+1,260,694
New +$4.77M
AUDC icon
34
AudioCodes
AUDC
$244M
$4.94M 0.62%
206,619
-99,434
-32% -$2.31M
DCPH
35
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$4.92M 0.62%
+119,500
New +$6.63M
XCUR icon
36
Exicure
XCUR
$10.2M
$4.86M 0.61%
21,899
+2,640
+14% +$835K
BEAM icon
37
Beam Therapeutics
BEAM
$2.63B
$4.76M 0.6%
+264,681
New +$5.75M
RCKT icon
38
Rocket Pharmaceuticals
RCKT
$340M
$4.67M 0.58%
335,016
-26,872
-7% -$532K
GRTX
39
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$4.52M 0.57%
475,677
+4,238
+0.9% +$54.6K
NGNE icon
40
Neurogene
NGNE
$656M
$4.52M 0.57%
19,850
+850
+4% +$175K
ORGS
41
DELISTED
Orgenesis Inc. Common Stock
ORGS
$4.22M 0.53%
+110,956
New +$4.85M
PTGX icon
42
Protagonist Therapeutics
PTGX
$8.79B
$3.71M 0.46%
526,075
-103,925
-16% -$779K
ASND icon
43
Ascendis Pharma A/S
ASND
$16B
$3.67M 0.46%
32,573
-41,200
-56% -$5.35M
TEVA icon
44
Teva Pharmaceuticals
TEVA
$40.8B
$3.2M 0.4%
356,713
+96,361
+37% +$987K
KA
45
DELISTED
Kineta, Inc. Common Stock
KA
$2.89M 0.36%
18,119
– –
VKTX icon
46
Viking Therapeutics
VKTX
$3.7B
$2.76M 0.35%
590,000
– –
PANW icon
47
Palo Alto Networks
PANW
$270B
$2.7M 0.34%
98,712
-87,144
-47% -$3.04M
ALDX icon
48
Aldeyra Therapeutics
ALDX
$92.9M
$2.64M 0.33%
1,069,089
– –
FVRR icon
49
Fiverr
FVRR
$321M
$2.64M 0.33%
104,839
-128,966
-55% -$3.47M
FLNA
50
Filana Therapeutics
FLNA
$48.8M
$2.53M 0.32%
+615,000
New +$4.07M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2020 Portfolio in Review

As of Q1 2020, Sphera Funds Management held 111 positions worth $800M, down 34% from $1.21B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sphera Funds Management withdrew a net $240M in Q1 2020, closing 33 positions and reducing 27 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 52% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in AstraZeneca worth $25.5M.

  • Sphera Funds Management's largest Q1 2020 buy was AstraZeneca: 285,000 shares worth $25.5M.
  • Sphera Funds Management added most to Merck in Q1 2020, an estimated $25.8M increase.
  • Sphera Funds Management's biggest Q1 2020 reduction was Johnson & Johnson, cutting an estimated $12.8M.
  • Sphera Funds Management fully exited BioMarin Pharmaceuticals in Q1 2020, selling an estimated $21.3M.
  • Sphera Funds Management's ten largest holdings make up 60% of its $800M portfolio in Q1 2020.
  • Sphera Funds Management opened 25 new positions and closed 33 in Q1 2020.
  • Sphera Funds Management's portfolio value fell 34% quarter-over-quarter to $800M.

Based on Sphera Funds Management's 13F filing for Q1 2020, filed 14 May 2020.